Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 46
Filtrar
1.
J Neurovirol ; 23(2): 250-259, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27882497

RESUMO

HIV in the central nervous system (CNS) mainly infects microglial cells which are known to express toll-like receptors (TLRs). This paper aimed to study the role of soluble TLR2 (sTLR2), sTLR4, and other inflammatory markers in cerebrospinal fluid (CSF) in HIV/Simian immunodeficiency virus (SIV)-related neurological sequelae. We determined sTLR2 and sTLR4 levels in CSF and serum/plasma of SIV-infected rhesus macaques with and without neurological sequelae, as well as in HIV-infected patients with and without cognitive impairments and Alzheimer's disease (AD) patients and matched controls. CSF cytokines and chemokines levels were analyzed in macaques as markers of neuroinflammation, while neopterin and S100B CSF concentrations were measured in HIV-infected patients as microglial and astrocyte marker, respectively. We found detectable levels of sTLR2 and sTLR4 in CSF of macaques and humans. Furthermore, CSF sTLR2 and sTLR4 concentrations were higher in SIV-infected macaques with neurological sequelae compared to those without neurological complications (p = 0.0003 and p = 0.0006, respectively). CSF IL-8 and monocyte chemoattractant protein-1 (MCP-1) levels were elevated in macaques with neurological sequelae, and a positive correlation was found between CSF levels of sTLR2/4 and IL-8 and MCP-1. Also in humans, elevated CSF sTLR4 levels were found in HIV-infected patients with cognitive impairments compared to HIV-infected patients with normal cognition (p = 0.019). Unlike CSF S100B levels, neopterin correlated positively with sTLR2 and sTLR4. No difference was found in plasma and CSF sTLR2 and sTLR4 levels between AD patients and control subjects (p = 0.26). In conclusion, CSF sTLR2 and sTLR4 may play a role in HIV/SIV-related neuroinflammation and subsequent neuropathology.


Assuntos
Doença de Alzheimer/líquido cefalorraquidiano , Disfunção Cognitiva/líquido cefalorraquidiano , Infecções por HIV/líquido cefalorraquidiano , Síndrome de Imunodeficiência Adquirida dos Símios/líquido cefalorraquidiano , Receptor 2 Toll-Like/imunologia , Receptor 4 Toll-Like/imunologia , Adulto , Doença de Alzheimer/sangue , Doença de Alzheimer/complicações , Doença de Alzheimer/virologia , Animais , Astrócitos/imunologia , Astrócitos/patologia , Astrócitos/virologia , Biomarcadores/sangue , Biomarcadores/líquido cefalorraquidiano , Estudos de Casos e Controles , Quimiocina CCL2/líquido cefalorraquidiano , Quimiocina CCL2/genética , Quimiocina CCL2/imunologia , Disfunção Cognitiva/sangue , Disfunção Cognitiva/complicações , Disfunção Cognitiva/virologia , Feminino , Expressão Gênica , HIV/imunologia , HIV/patogenicidade , Infecções por HIV/sangue , Infecções por HIV/complicações , Infecções por HIV/virologia , Humanos , Interleucina-8/líquido cefalorraquidiano , Interleucina-8/genética , Interleucina-8/imunologia , Macaca mulatta , Masculino , Microglia/imunologia , Microglia/patologia , Microglia/virologia , Pessoa de Meia-Idade , Neopterina/líquido cefalorraquidiano , Neopterina/genética , Neopterina/imunologia , Subunidade beta da Proteína Ligante de Cálcio S100/líquido cefalorraquidiano , Subunidade beta da Proteína Ligante de Cálcio S100/genética , Subunidade beta da Proteína Ligante de Cálcio S100/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/sangue , Síndrome de Imunodeficiência Adquirida dos Símios/virologia , Vírus da Imunodeficiência Símia/imunologia , Vírus da Imunodeficiência Símia/patogenicidade , Solubilidade , Receptor 2 Toll-Like/genética , Receptor 4 Toll-Like/genética
2.
Clin Exp Immunol ; 185(1): 42-9, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26850369

RESUMO

In humans, CD16 and CD56 are used to identify functionally distinct natural killer (NK) subsets. Due to ubiquitous CD56 expression, this marker cannot be used to distinguish between NK cell subsets in chimpanzees. Therefore, functional analysis of distinct NK subsets during hepatitis C virus (HCV) infection has never been performed in these animals. In the present study an alternative strategy was used to identify four distinct NK subsets on the basis of the expression of CD16 and CD94. The expression of activating and inhibiting surface receptors showed that these subsets resemble human NK subsets. CD107 expression was used to determine degranulation of the different subsets in naive and HCV-infected chimpanzees. In HCV-infected chimpanzees increased spontaneous cytotoxicity was observed in CD94(high/dim) CD16(pos) and CD94(low) CD16(pos) subsets. By contrast, increased natural cytotoxicity receptor (NCR)- mediated degranulation after NKp30 and NKp44 triggering was demonstrated in the CD94(dim) CD16(neg) subset. Our findings suggest that spontaneous and NCR-mediated cytotoxicity are effector functions of distinct NK subsets in HCV-infected chimpanzees.


Assuntos
Linhagem da Célula/imunologia , Citotoxicidade Imunológica , Hepacivirus/imunologia , Hepatite C/imunologia , Células Matadoras Naturais/imunologia , Animais , Doenças dos Símios Antropoides , Degranulação Celular/efeitos dos fármacos , Citometria de Fluxo , Regulação da Expressão Gênica , Hepatite C/patologia , Hepatite C/virologia , Imunofenotipagem , Interleucina-2/farmacologia , Interleucinas/farmacologia , Células Matadoras Naturais/classificação , Células Matadoras Naturais/citologia , Células Matadoras Naturais/efeitos dos fármacos , Ativação Linfocitária/efeitos dos fármacos , Proteína 1 de Membrana Associada ao Lisossomo/genética , Proteína 1 de Membrana Associada ao Lisossomo/imunologia , Subfamília D de Receptores Semelhantes a Lectina de Células NK/genética , Subfamília D de Receptores Semelhantes a Lectina de Células NK/imunologia , Receptor 2 Desencadeador da Citotoxicidade Natural/genética , Receptor 2 Desencadeador da Citotoxicidade Natural/imunologia , Receptor 3 Desencadeador da Citotoxicidade Natural/genética , Receptor 3 Desencadeador da Citotoxicidade Natural/imunologia , Pan troglodytes , Receptores de IgG/genética , Receptores de IgG/imunologia
3.
Clin Exp Immunol ; 174(1): 161-71, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23750720

RESUMO

Macaques provide important animal models in biomedical research into infectious and chronic inflammatory disease. Therefore, a proper understanding of the similarities and differences in immune function between macaques and humans is needed for adequate interpretation of the data and translation to the human situation. Dendritic cells are important as key regulators of innate and adaptive immune responses. Using a new whole blood assay we investigated functional characteristics of blood plasmacytoid dendritic cells (pDC), myeloid dendritic cells (mDC) and monocytes in rhesus macaques by studying induction of activation markers and cytokine expression upon Toll-like receptor (TLR) stimulation. In a head-to-head comparison we observed that rhesus macaque venous blood contained relatively lower numbers of pDC than human venous blood, while mDC and monocytes were present at similar percentages. In contrast to humans, pDC in rhesus macaques expressed the interleukin (IL)-12p40 subunit in response to TLR-7/8 as well as TLR-9 stimulation. Expression of IL-12p40 was confirmed by using different monoclonal antibodies and by reverse transcription-polymerase chain reaction (RT-PCR). Both in humans and rhesus macaques, TLR-4 stimulation induced IL-12p40 expression in mDC and monocytes, but not in pDC. The data show that, in contrast to humans, pDC in macaques are able to express IL-12p40, which could have consequences for evaluation of human vaccine candidates and viral infection.


Assuntos
Células Dendríticas/imunologia , Subunidade p40 da Interleucina-12/biossíntese , Receptor 7 Toll-Like/agonistas , Receptor 7 Toll-Like/sangue , Receptor 8 Toll-Like/agonistas , Receptor 8 Toll-Like/sangue , Receptor Toll-Like 9/agonistas , Receptor Toll-Like 9/sangue , Animais , Células Dendríticas/metabolismo , Humanos , Subunidade p40 da Interleucina-12/sangue , Subunidade p40 da Interleucina-12/genética , Macaca mulatta
4.
Tissue Antigens ; 78(4): 256-62, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21929574

RESUMO

Tripartite motif 5α (TRIM5α) is a potent antiretroviral immune factor present in the cytoplasm of cells of most tissue types. The rhesus macaque TRIM5 gene has been shown to display polymorphism, with different variants being divided into three groups (TRIM5(TFP), TRIM5(Q), and TRIM5(CypA)), which may have divergent retroviral effects on infection. Along with rhesus macaques, cynomolgus macaques are also used in simian immunodeficiency virus (SIV) infection studies. As a consequence, TRIM5 genotyping of these animals will contribute to interpreting the outcome of such studies. The present communication covers Burmese, Chinese, and a large cohort of Indian-origin rhesus macaques, and describes the first large cohort study on TRIM5 polymorphism in outbred cynomolgus macaques. We demonstrate the presence of the TRIM5(TFP) group in cynomolgus macaques. In addition, we have re-evaluated historical samples of rhesus macaques challenged with SIV(mac251), a virus that has been reported to be partially suppressed by particular rhesus macaque TRIM5 variants.


Assuntos
Alelos , Proteínas de Transporte/genética , Macaca mulatta/genética , Polimorfismo Genético , Vacinas contra a SAIDS/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/genética , Vírus da Imunodeficiência Símia , Animais , Sudeste Asiático , Proteínas de Transporte/imunologia , Genótipo , Macaca fascicularis , Macaca mulatta/imunologia , Vacinas contra a SAIDS/genética , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle
5.
J Med Virol ; 79(5): 474-82, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17385685

RESUMO

The rapidly spreading HIV epidemic requires a vaccine that elicits potent mucosal immunity to halt or slow transmission. Induction of these responses will depend on the use of appropriate adjuvants and targeting of the mucosal immune system. Previously, immune stimulating complexes (ISCOM) have shown great potency as adjuvant in the induction of mucosal responses in mice and systemic responses in non-human primates. In this study, HIV formulated in PR8-Flu ISCOM adjuvant was applied to immunize rhesus macaques against HIV; targeting the mucosa either via intranasal (IN) application or via targeted lymph node immunization (TLNI). While, strong systemic, HIV specific, cytokine, lymphoproliferative, and antibody responses were induced via the TLNI route, the IN application generated only low responses. Furthermore, all four animals immunized via TLNI developed vaginal IgA antibodies against gp120. In conclusion, in contrast to what has been demonstrated in mice, the IN application of PR8-Flu ISCOM did not induce strong immune responses in rhesus macaques unlike those immunized by the TLNI route.


Assuntos
Vacinas contra a AIDS/administração & dosagem , Adjuvantes Imunológicos/administração & dosagem , Anticorpos Anti-HIV/análise , Infecções por HIV/imunologia , HIV-1/imunologia , ISCOMs/administração & dosagem , Imunização , Vacinas contra a AIDS/imunologia , Administração Intranasal , Animais , Especificidade de Anticorpos , Feminino , Proteína do Núcleo p24 do HIV/administração & dosagem , Proteína do Núcleo p24 do HIV/imunologia , Proteína gp120 do Envelope de HIV/administração & dosagem , Proteína gp120 do Envelope de HIV/imunologia , Humanos , Esquemas de Imunização , Imunoglobulina A/análise , Injeções Intralinfáticas , Macaca mulatta , Vacinas de Subunidades Antigênicas/administração & dosagem , Vagina/imunologia
6.
Clin Exp Immunol ; 128(1): 155-62, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11982603

RESUMO

The loss of CD4 lymphocytes in HIV disease associates with opportunistic infections. Since diverse CD4 T cell clones respond to an opportunistic pathogen, we asked whether CD4 depletion deletes selected clones in the repertoire (vertical depletion) or it affects all clones by reducing the cell number in each progeny without affecting the overall number of clones (horizontal depletion). Understanding this point may help explain the mode of CD4 depletion and the mode of immunoreconstitution after therapy. Therefore we examined the CD4 T cell repertoire specific for Pneumocystis carinii, a relevant opportunistic pathogen in AIDS, in HIV-infected, asymptomatic individuals. We identified two patients of 36 asymptomatics for lack of proliferation to P. carinii, suggesting selective depletion of specific CD4 cells. To investigate clonal heterogeneity of P. carinii-responsive CD4 lymphocytes, specific CD4 T cell lines were generated and studied by TCR BV gene family usage and CDR3 length analysis (spectratyping). Clonal heterogeneity was similar in antigen-specific CD4 lines generated from P. carinii non-responding HIV seropositives and from controls. Thus, despite undetectable response to the pathogen, residual specific cells probably prevent overt infection and, when expanded in vitro, exhibit a clonal diversity similar to normal controls. These findings suggest a horizontal, rather than vertical, depletion in these asymptomatic patients.


Assuntos
Linfócitos T CD4-Positivos/imunologia , Deleção Clonal , Soropositividade para HIV/imunologia , Pneumocystis/imunologia , Infecções Oportunistas Relacionadas com a AIDS/imunologia , Adulto , Linhagem Celular , Células Clonais , Genes Codificadores da Cadeia beta de Receptores de Linfócitos T , Humanos , Região Variável de Imunoglobulina/genética , Ativação Linfocitária , Modelos Imunológicos , Infecções por Pneumocystis/imunologia
7.
AIDS ; 15(18): 2359-69, 2001 Dec 07.
Artigo em Inglês | MEDLINE | ID: mdl-11740186

RESUMO

OBJECTIVE: HIV-1 infection in humans has been reported to lead to a shift in the cytokine balance, with a relative decrease in T helper 1 type cytokines, especially IL-2. On the basis of the expression of CD45RA, in combination with homing markers CD62L or alpha4beta7, T helper cells can be sub-divided into naive, activated naive, central memory and effector memory cells as well as gut-homing subpopulations. In addition, each subset may have the potential to express distinct cytokines. At present it is unclear whether the changes in cytokine expression observed in HIV-1-infected individuals are secondary to changes within the composition of CD4 T cell subsets or are caused by changes in cytokine expression within each subset. MATERIALS AND METHODS: A new technique was developed to detect cytokine expression in phorbol 12-myristate 13-acetate/ionomycin-activated CD62L and alpha4beta7-expressing CD4 T cell subsets, using the protease inhibitor KD-IX-73-4. RESULTS: In SIV-infected macaques that develop AIDS a marked decrease in IL-2 expression was found within central, effector, or gut-homing memory cell subsets, whereas the expression of IL-2 in naive T cell subsets remained unaffected. This reduced IL-2 expression by memory cells and not a loss of the frequency of CD4 memory cells accounted for the reduced expression of IL-2 by CD4 T cells during SIV infection. CONCLUSION: As defined by the cell surface markers utilized, it appears that progression to AIDS is associated with functional impairment of memory cells, but not changes in lymphocyte circulation patterns.


Assuntos
Linfócitos T CD4-Positivos/imunologia , Memória Imunológica/imunologia , Interleucina-2/metabolismo , Síndrome de Imunodeficiência Adquirida dos Símios/fisiopatologia , Vírus da Imunodeficiência Símia/imunologia , Animais , Citocinas/metabolismo , Modelos Animais de Doenças , Progressão da Doença , Citometria de Fluxo/métodos , Humanos , Macaca mulatta , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Subpopulações de Linfócitos T/imunologia , Linfócitos T Auxiliares-Indutores/imunologia
8.
Immunol Lett ; 79(1-2): 101-7, 2001 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-11595296

RESUMO

Dendritic cells (DC) have been implicated in the pathogenesis of both human and simian immunodeficiency viruses (HIV and SIV, respectively). The DC-specific HIV-1 trans-receptor DC-SIGN is thought to be essential for viral dissemination by DC. Abundant expression in lymphoid tissues also implies a function for DC-SIGN in chronic HIV-1 infections, in facilitating persistent infection of T cells. We have therefore isolated the rhesus macaque and chimpanzee homologues of DC-SIGN to investigate their function in a primate model. Both rhesus macaque and chimpanzee DC-SIGN are highly similar to the human homologue. Three monoclonal antibodies against human DC-SIGN, AZN-D1, -D2 and -D3, cross-react with rhesus macaque DC-SIGN, whereas AZN-D2 does not cross-react with chimpanzee DC-SIGN. The primate homologues are abundantly expressed in lymphoid tissues such as lymph nodes, as well as in mucosal tissues involved in sexual transmission of HIV-1, and are functionally similar to human DC-SIGN. They have a high affinity for the immunological ligands of DC-SIGN: ICAM-2 and -3. Moreover, both homologues bind the HIV-1 envelope glycoprotein gp120 and therefore can act as a HIV-1 trans-receptor in the same way as human DC-SIGN. These data demonstrate that primate models are suitable to further dissect the role of DC-SIGN in the transmission and pathogenesis of infection with immunodeficiency viruses.


Assuntos
Moléculas de Adesão Celular , Lectinas Tipo C , Lectinas/imunologia , Macaca mulatta/imunologia , Glicoproteínas de Membrana , Pan troglodytes/imunologia , Receptores de Superfície Celular/imunologia , Receptores de HIV/imunologia , Vírus da Imunodeficiência Símia/imunologia , Proteínas do Envelope Viral , Sequência de Aminoácidos , Animais , Anticorpos Monoclonais , Sequência de Bases , Reações Cruzadas , DNA Complementar/genética , Células Dendríticas/imunologia , Expressão Gênica , Proteína gp120 do Envelope de HIV/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , Humanos , Lectinas/genética , Ligantes , Macaca mulatta/genética , Dados de Sequência Molecular , Pan troglodytes/genética , Receptores de Superfície Celular/genética , Receptores de HIV/genética , Homologia de Sequência de Aminoácidos , Especificidade da Espécie
9.
J Virol ; 75(19): 9328-38, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11533196

RESUMO

End-stage simian immunodeficiency virus (SIV) isolates are suggested to be the most fit of the evolved virulent variants that precipitate the progression to AIDS. To determine if there were common characteristics of end-stage variants which emerge from accelerated cases of AIDS, a molecular clone was derived directly from serum following in vivo selection of a highly virulent SIV isolate obtained by serial end-stage passage in rhesus monkeys (Macaca mulatta). This dominant variant caused a marked cytopathic effect and replicated to very high levels in activated but not resting peripheral blood lymphocytes. Furthermore, although this clone infected but did not replicate to detectable levels in rhesus monocyte-derived macrophages, these cells were able to transmit infection to autologous T cells upon contact. Interestingly, although at low doses this end-stage variant did not use any of the known coreceptors except CCR5, it was able to infect and replicate in human peripheral blood mononuclear cells homozygous for the Delta 32 deletion of CCR5, suggesting the use of a novel coreceptor. It represents the first pathogenic molecular clone of SIV derived from viral RNA in serum and provides evidence that not only the genetic but also the biological characteristics acquired by highly fit late-stage disease variants may be distinct in different hosts.


Assuntos
Genoma Viral , Imunodeficiência Combinada Severa/virologia , Vírus da Imunodeficiência Símia/genética , Sequência de Aminoácidos , Animais , Humanos , Macaca mulatta , Dados de Sequência Molecular , Filogenia , Imunodeficiência Combinada Severa/sangue , Vírus da Imunodeficiência Símia/isolamento & purificação , Vírus da Imunodeficiência Símia/patogenicidade , Virulência/genética , Replicação Viral
10.
J Infect Dis ; 184(2): 136-43, 2001 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-11424009

RESUMO

Recent evidence suggests a much higher prevalence of human immunodeficiency virus type 1 (HIV-1) recombinants than previously anticipated. These recombinants arise from secondary HIV infections in individuals already infected with the virus. It remains unclear why some individuals acquire secondary HIV-1 infections and others do not. To address this question, a study was undertaken of a small cohort of chimpanzees with well-defined HIV-1 infection. After exposure to an infectious dose of heterologous primary isolate, 4 of 8 HIV-1 seropositive chimpanzees resisted secondary infection, whereas 2 naive controls became readily infected. Only animals who were immunologically boosted were protected. Protection from heterologous secondary exposure appeared to be related to the repertoire of the cytolytic CD8(+) T cell responses to HIV-1. Data suggested that immunologic boosting by HIV-1 antigens or exposure to subinfectious doses of virus may be important events in sustaining sufficient immunity to prevent secondary infections from occurring.


Assuntos
Vacinas contra a AIDS/administração & dosagem , Síndrome da Imunodeficiência Adquirida/imunologia , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Linfócitos T Citotóxicos/imunologia , Vacinas contra a AIDS/imunologia , Animais , Infecções por HIV/imunologia , Pan troglodytes
11.
Hum Immunol ; 62(3): 208-14, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11250038

RESUMO

Corticosteroids are used therapeutically as potent immunosuppressive and antiinflammatory drugs for a broad spectrum of diseases. Although corticosteroids are known to inhibit the production of many cytokines in activated T cells, there is also evidence for increases in IL-4 and in some cases IFNgamma production. These conflicting results may be caused by contrary effects of corticosteroids on different cell types involved in immune regulation, for instance antigen presenting cells (APC) versus T cells. In the present study we simultaneously investigated the effect of local as well as systemic application of glucocorticoids (GCC) on the phenotype of APC in the skin as well as the lymph nodes in a model primate species, the rhesus macaque. Using a range of APC markers, including CD68, HAM56, HLA-DR, CD1a, p55, RFD-1, and costimulatory molecules CD40, CD80, and CD86 we document the close phenotypic resemblance of rhesus and human APC. We noted that topical GCC treatment specifically lead to a marked decrease in the number of CD1a expressing cells in the draining lymph nodes. However, the number of CD1a positive cells in peripheral lymph nodes was not affected by systemic GCC treatment. Importantly, by performing double staining of CD1a with RFD-1 we observed a shift in the expression pattern of these dendritic cell markers in the lymph nodes, with an increase in the number of RFD-1 single positive cells relative to CD1a single positive and CD1a/RFD-1 double positive cells. These findings suggest that GCC treatment results in the presence of phenotypically more mature APC.


Assuntos
Anti-Inflamatórios/imunologia , Clobetasol/imunologia , Células Dendríticas/imunologia , Dexametasona/imunologia , Glucocorticoides/imunologia , Administração Tópica , Animais , Anti-Inflamatórios/farmacologia , Células Apresentadoras de Antígenos/classificação , Células Apresentadoras de Antígenos/imunologia , Antígenos CD/análise , Braço , Clobetasol/análogos & derivados , Clobetasol/farmacologia , Células Dendríticas/classificação , Células Dendríticas/citologia , Dexametasona/farmacologia , Glucocorticoides/farmacologia , Linfonodos/citologia , Linfonodos/efeitos dos fármacos , Linfócitos/classificação , Linfócitos/imunologia , Macaca mulatta , Masculino , Coxa da Perna
12.
J Med Primatol ; 29(3-4): 268-73, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11085589

RESUMO

A large number of recombinant of viral and bacterial systems have been engineered as vectors to express foreign genes for vaccination and/or gene therapy. A common problem is the immune response to the vector itself. The presence of anti-vector immune responses may preclude sufficient 'priming' or immunogenicity if pre-existing immune responses are present, or they may impair optimal 'boosting' upon repeated immunization or delivery with the same vector. To circumvent this problem we developed a strategy using different chimeric vectors which share only the expression of common specific antigens desired for immunization. This approach not only has the advantage of avoiding increased anti-vector responses, but allows the use of combinations of vectors which could subsequently present the same or related antigen differently to the immune system as well as at alternative sites to induce the optimal type of immunity against the pathogen of interest.


Assuntos
Antígenos Virais/imunologia , Vacinas contra a SAIDS/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Vírus da Imunodeficiência Símia/imunologia , Vacinas Sintéticas/imunologia , Animais , Antígenos Virais/genética , Quimera , Genes env , Genes gag , Genes nef , Genes pol , Genes rev , Genes tat , Macaca mulatta , Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle
13.
J Med Primatol ; 28(4-5): 224-32, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10593489

RESUMO

In two previous studies, we have demonstrated the successful protection of human immunodeficiency virus type 1 (HIV-1)-vaccinated rhesus macaques from challenge with SHIV(SF13) with envelop immunogens derived from the closely related HIV-1(SF2) strain. Here we report on two follow-up studies in which we aimed to broaden immunity in order to elicit protection from a more diverse heterologous challenge with SHIV(SF33). In the first study, animals were boosted once with HIV-1(SF33) V2 and V3 peptides that were cross-linked to influenza immune-stimulating complexes (ISCOMs). In the second study, monkeys were boosted twice at 12-week intervals, using a heterologous recombinant gp120 derived from HIV-1(SF33) that was either incorporated into ISCOMs or mixed with the MF59 adjuvant. In both studies, the animals were challenged with 50 monkey infectious doses of SHIV(SF33) 4 weeks after the final boost. All controls became readily infected with the heterologous challenge virus SHIV(SF33). Neither boosting with heterologous SF33 peptides or gp120 afforded protection from infection to SF2-vaccinated animals that had previously resisted SHIV(SF13) challenge. These results demonstrate the importance of developing vaccine strategies that are capable of generating broad immune responses early in the immunization protocol. Furthermore, these findings may illustrate the potential pitfalls of early antigenic sin.


Assuntos
Vacinas contra a AIDS/imunologia , HIV-1/imunologia , Proteínas do Envelope Viral/imunologia , Animais , Epitopos/imunologia , Proteína gp120 do Envelope de HIV/imunologia , Imunização/veterinária , Macaca mulatta , Orthomyxoviridae/imunologia , Fragmentos de Peptídeos/imunologia , Vírus da Imunodeficiência Símia/imunologia , Vacinas Atenuadas/imunologia , Carga Viral
14.
Br J Dermatol ; 140(1): 17-25, 1999 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10215763

RESUMO

Basal cell carcinomas (BCCs) of the skin exhibit a wide range of histological growth patterns as well as a highly variable rate of invasiveness. A large body of experimental and clinical studies supports a role for the CD44 glycoprotein family in the latter process. In the present study, we explored the distribution and the level of expression of pan-CD44, CD44v3, CD44v5 and CD44v6 in BCCs. The use of paraffin sections, combined with an antigen retrieval procedure, yielded far more detailed data than would have been possible with frozen sections. On average, the level of expression of the four CD44 isoforms studied appeared to differ relatively little. However, tumours or tumour areas consisting of thin tumour cell strands showed a significantly stronger expression of all four isoforms than those consisting of solid tumour cell groups. Furthermore, the highest CD44 expression was frequently observed in the smallest tumour cell strands in the tumour periphery. In these strands, the label seemed to be located not only at the tumour cell-tumour cell interface, as in other tumour areas, but also on the tumour cell surfaces facing the stroma. We are presently assessing the exact localization of CD44 at the cellular level by immunoelectron microscopy. In most cases, different growth patterns with significantly different levels of CD44 expression were found side by side within individual tumours. CD44 expression is therefore not a static tumour cell characteristic but is correlated with tumour architecture and tumour-stroma interaction.


Assuntos
Carcinoma Basocelular/metabolismo , Receptores de Hialuronatos/metabolismo , Neoplasias Cutâneas/metabolismo , Actinas/análise , Carcinoma Basocelular/patologia , Divisão Celular , Corantes , Humanos , Imuno-Histoquímica , Músculo Liso/química , Invasividade Neoplásica , Inclusão em Parafina , Projetos Piloto , Neoplasias Cutâneas/patologia
15.
Immunol Lett ; 66(1-3): 61-7, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10203035

RESUMO

Cell mediated immune responses to HIV-1 and CTL responses in particular differ dramatically in infected individuals. This may largely be influenced by the immunogenetic differences of different individuals such as those encoded by the MHC. These differences may be difficult to dissect due to the immunosuppressive nature of HIV-1 infection itself. In order to reduce the variables associated with effects of the virus, one recombinant viral antigen was chosen from a particular HIV-1 variant (rgp120 of the clinical isolate HIV-1w6.1D). To minimise differences between outbred hosts, we chose two sibling chimpanzees from which the family pedigree and genetic segregation with respect to polymorphic MHC molecules was known. Immunisation induced strong antigen specific antibody and T-helper immune responses. The magnitude and persistence of the humoral and T-helper immune responses were comparable in both chimpanzees. However, CTL responses were only observed in one sibling. These responses were subsequently mapped to several distinct epitopes. The CTL response to the immunodominant epitope was found to be presented in the context of a MHC molecule which was shared by both siblings. The absence of a CTL response in the other sibling is not yet understood, but could not be attributed to MHC alleles that were not shared by these two chimpanzees. These findings suggest that other polymorphic immunoregulatory mechanisms such as those involved in antigen processing and presentation influence host CTL responses to HIV-1.


Assuntos
HIV-1/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Linfócitos T Citotóxicos/imunologia , Animais , Mapeamento de Epitopos , Epitopos de Linfócito T/imunologia , Feminino , Haplótipos , Humanos , Masculino , Pan troglodytes , Linhagem
16.
Immunol Lett ; 66(1-3): 189-95, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10203054

RESUMO

The specific immune mechanisms necessary and/or sufficient to elicit HIV-vaccine protection remain undefined. Utilising the SHIV rhesus macaque model the immunogenicity as well as the efficacy of ten different HIV-1 vaccine candidates was evaluated. Comparison of the immune responses induced, with the ability of the vaccine to protect from SHIV infection provided a means to determine which type of immune responses were necessary for protection. Vaccine candidates included VLPs, DNA, subunit protein with novel adjuvant formulations, ISCOMs and pox-virus vectors. Protection from SHIV infection was achieved in approximately half of the animals which received a primary intravenous cell-free challenge. The presence of CTL in the absence of other effector responses did not correlate with protection from this route and type of challenge. Virus neutralising antibodies (Nab) appeared to be necessary but alone were insufficient for protection. If Ag-specific IFN-gamma and/or IL-4 as well as lymphoproliferative (LP) responses were found with the lack of a detectable IL-2 response, then protection was not observed. Immunity correlated with the magnitude of Nab responses, beta-chemokines and as well as balanced, qualitative T-helper responses.


Assuntos
Vacinas contra a AIDS/imunologia , HIV-1/imunologia , Vírus Reordenados/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle , Vírus da Imunodeficiência Símia/imunologia , Animais , Formação de Anticorpos , Quimiocinas CC/imunologia , Ensaios Clínicos como Assunto , Anticorpos Anti-HIV/imunologia , Humanos , Imunidade Celular , Macaca mulatta , Testes de Neutralização , Linfócitos T Citotóxicos/imunologia , Linfócitos T Auxiliares-Indutores/imunologia
17.
AIDS Res Hum Retroviruses ; 15(4): 365-73, 1999 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-10082120

RESUMO

Lymphoid tissues are the focus of critical events in HIV pathogenesis. Persistent and high levels of virus production, extensive trapping of virus particles in germinal centers, and progressive degenerative changes in lymph node architecture are characteristics of progressive HIV-1 infection. Infiltrates of granzyme B- and TIA-expressing CD8+ "cytotoxic" T lymphocytes (CTLs) precede involution of germinal centers in humans who develop AIDS. Similar to humans, HIV-1 infection in chimpanzees is active and persistent. However, in contrast to humans, they remain relatively resistant to AIDS. Lymph node biopsies from chimpanzees infected with HIV-1 or a related chimpanzee lentivirus were studied for the level and pattern of virus expression, changes in lymphoid architecture, CD8+ T cell infiltrates and the presence or absence of CTL markers. In stark contrast to HIV-1-infected humans, lymph nodes from infected chimpanzees had little virus deposition in germinal centers and a paucity of virus-expressing cells. Although some of the lymph nodes examined from infected animals had moderate follicular hyperplasia with infiltrating CD8+ T cells, none had evidence of follicular fragmentation. Most importantly, in marked contrast to infected humans, CD8+ T cells infiltrating the germinal center were negative for the CTL marker granzyme B. This evidence suggests that the infiltration of CD8+ CTLs into the germinal centers of lymph nodes may be a key determinant in AIDS pathogenesis.


Assuntos
Síndrome da Imunodeficiência Adquirida/imunologia , HIV-1/imunologia , Linfócitos T Citotóxicos/imunologia , Síndrome da Imunodeficiência Adquirida/patologia , Animais , Granzimas , Humanos , Imunidade Inata/imunologia , Linfonodos/citologia , Linfonodos/imunologia , Linfonodos/virologia , Pan troglodytes , Serina Endopeptidases/análise
18.
J Immunol ; 162(4): 2308-14, 1999 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-9973508

RESUMO

Certain HIV-1 infected humans that do not progress to AIDS have been documented to share particular MHC class I alleles that appear to correlate with long-term survival. HIV-1-infected chimpanzees are relatively resistant to progression to AIDS. Out of a group of 10 chimpanzees with CTL activity and nonprogressive HIV-1 infection, 2 animals with prominent cytolytic CD3+CD8+ T cell responses to HIV-1 Ags were studied in detail. Characterization of these CTL revealed that they contained the granzymes A and B, T cell intracellular Ag-1, and perforin and induced calcium-dependent cytolysis that correlated with the presence of apoptotic nuclei in target cells. These CTL responses were directed against two gagpeptides, which were found to be identical to previously described epitopes recognized in the context of HLA-B27 and HLA-B57 molecules. The latter two restriction elements occur with increased frequency in human long-term survivor cohorts. Phylogenetic comparisons revealed that the chimpanzee restriction elements, Patr-B*02and -B*03, described here do not show any obvious similarity with the HLA-B*27 and -B*57 alleles, suggesting that CTL responses to HIV-1 in distinct primate species may be controlled by different types of HLA-B-like molecules. The CTL responses in these two chimpanzees are directed, however, against highly conserved epitopes mapping across the majority of HIV-1 clades.


Assuntos
Síndrome da Imunodeficiência Adquirida/imunologia , Sequência Conservada/imunologia , Epitopos de Linfócito T/metabolismo , Sobreviventes de Longo Prazo ao HIV , HIV-1/imunologia , Pan troglodytes/imunologia , Linfócitos T Citotóxicos/imunologia , Síndrome da Imunodeficiência Adquirida/genética , Síndrome da Imunodeficiência Adquirida/veterinária , Sequência de Aminoácidos , Animais , Citotoxicidade Imunológica/genética , Mapeamento de Epitopos , Epitopos de Linfócito T/genética , Epitopos de Linfócito T/isolamento & purificação , Produtos do Gene gag/imunologia , Antígenos de Histocompatibilidade Classe I/genética , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Imunofenotipagem , Dados de Sequência Molecular , Doenças dos Primatas/genética , Doenças dos Primatas/imunologia , Linfócitos T Citotóxicos/química , Linfócitos T Citotóxicos/metabolismo
19.
Res Immunol ; 149(7-8): 647-9, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9851517

RESUMO

This project is devoted to the development of novel cellular vaccines designed to treat cancer patients. These cellular vaccines present and enhance immunogens, which will elicit a potent immune response. The goal is to achieve safe and effective immune reaction against the patient's own tumour. (1) Autologous cellular vaccines are prepared by processing circulating blood mononuclear cells outside of the patient's body (ex vivo) to differentiate them into antigen-presenting cells (APCs). Monocyte-derived APCs (MD-APCs) are then grown in the presence of exogenous target antigens (tumour cell debris, or apoptotic bodies) to become fully mature APCs. (2) Functionality for antigen presentation to T cells of ex vivo MD-APCs is evaluated in vivo. (3) Cellular vaccines are tested in selected rodent animal models. Efficiency and immune response are monitored in pertinent experimental systems for cancer. Pharmacological data are generated for clinical investigation. Tolerance and biologic effects are documented in primates. (4) The first clinical trials on cancer patients are taking place in 1998 on melanoma and prostate cancer to validate the concept. Specialized cell processors with dedicated software and standardized controls are being developed and used for the preparation of cellular vaccines. (5) The evaluation of new non-viral vectors and the validation of new non-viral transfection methods of mononuclear cells with marker genes is in progress and will lead to the ex vivo transfection of genes coding for immunostimulating cytokines or for tumour antigens in MD-APCs. Efficiency will be validated in vitro and in animal models. The ex vivo and animal model studies validate the clinical relevance of this new cellular immunotechnology. Clinical validation of individual autologous cellular vaccines in specific indications for which no treatment is presently available will allow the development of cellular and gene immunotherapy for other types of cancers.


Assuntos
Células Apresentadoras de Antígenos/imunologia , Vacinas Anticâncer/imunologia , Monócitos/imunologia , Linfócitos T/imunologia , Animais , Células Apresentadoras de Antígenos/citologia , Ensaios Clínicos como Assunto , Vetores Genéticos , Humanos , Masculino , Melanoma/prevenção & controle , Monócitos/citologia , Neoplasias da Próstata/prevenção & controle
20.
Biochem Biophys Res Commun ; 245(1): 172-6, 1998 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-9535803

RESUMO

Endothelium plays a central role in the regulation of site and inflammation specific leukocyte migration. Some of the mediators involved in leukocyte migration, such as chemokines, can bind to heparan sulfate on the endothelium resulting in immobilization near their sites of production. Because CD44 variants expressing V3 have been shown to carry heparan sulfate side chains and to interact through these side chains with heparan sulfate binding growth factors, we investigated the expression of CD44 variants on endothelium. We found a strong expression of V5, V7-8 and V10 CD44 variants and a weaker expression of V3 and V6 CD44 variants on endothelium by using immuno-histochemistry and by FACS analysis. Expression of CD44 V3 variants was confirmed at both the protein and mRNA levels by Western blotting and by reverse transcriptase-PCR respectively. Expression of CD44 variants was unaffected by IL-1beta, IL-8, TNFalpha, IFNgamma or IL-4 treatment, indicating either constitutive expression of these variants or involvement of other cytokines in their regulation.


Assuntos
Endotélio Vascular/química , Substâncias de Crescimento/metabolismo , Receptores de Hialuronatos/fisiologia , Imunidade/imunologia , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/metabolismo , Células Cultivadas , Citocinas/farmacologia , Citometria de Fluxo , Regulação da Expressão Gênica/imunologia , Receptores de Hialuronatos/análise , Imuno-Histoquímica , Inflamação/metabolismo , RNA Mensageiro/metabolismo , Veias Umbilicais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...